20/20 Biolabs Inc. AIDX
—
0.43
0.01
2.38%
as of 25 Sep
- Market cap
- $5.4M
- P/E
- 0.0×
Follow AIDX
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+2 more quarters Free account |
P/S ratio |
2.73 | 0.00 | — | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(9.80) | (11.17) | — | (59.91) | |
P/B ratio |
3.66 | 5.64 | — | 0.00 | |
Price to Tangible BV |
9.42 | 9.48 | — | 0.00 | |
EV/Sales |
1.07 | 0.00 | — | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(0.53) | (2.62) | — | (20.70) | |
EV/FCF |
(0.53) | (2.62) | — | (20.70) | |
Quick Ratio |
1.90 | 1.71 | 0.50 | — | |
Current Ratio |
1.99 | 1.82 | 0.60 | — | |
Net Debt/EBITDA |
4.77 | 3.29 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 5.28% | 16.77% | 0.00% | |
Debt/Equity |
0.00 | 0.11 | (36.15) | 0.00 | |
Asset Turnover |
0.71 | 0.00 | — | — | |
Operating CF/Net income |
0.22 | 0.61 | 0.00 | 0.64 | |
Capex/Depreciation |
0.00 | (0.02) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
35.26% | 43.44% | — | 36.27% | |
Selling, General and Administrative Expense of Revenue |
176.75% | 382.80% | — | 152.27% | |
Intangible Assets out of Total Assets |
0.16 | 0.18 | 0.26 | 0.00 | |
Share Based Compensation of Revenue |
50.82% | 36.33% | — | 24.22% | |
Graham Net Nets |
0.36 | 0.11 | — | (0.02) | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(158.71%) | (158.71%) | — | (158.71%) | |
Free Cash Flow Yield |
(73.27%) | (29.39%) | — | (4.82%) | |
Revenue per Share |
0.07 | 0.05 | — | 0.11 | |
Operating CF per Share |
(0.06) | (0.17) | 0.00 | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.17) | 0.00 | (0.11) | |
Cash per Share |
0.42 | 0.55 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.29 | 0.36 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.29 | 0.36 | 0.00 | 0.00 | |
Free Cash Flow |
(0.61) | (1.29) | (1.92) | (0.53) | |
Working Capital |
2.52 | 2.12 | (0.99) | — | |
Capital Expenditures |
0.00 | (0.01) | 0.00 | — | |
Net Current Asset Value |
2.11 | 1.65 | (2.69) | 0.00 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.00 | 0.00 | |
Net Profit Margin |
(376.77%) | (600.06%) | — | (157.15%) | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Assets |
3.06 | 4.69 | — | — |
Columns are period end dates